Adeka (4401) Q2 2026 earnings summary

Executive summary

• Net sales for the first half of FY2025 were ¥195.7 billion, up 0.3% year-over-year, with operating profit rising 8.0% to ¥19.7 billion and profit attributable to owners at ¥12.4 billion, up 8.1%.

• Net profit per share increased to ¥122.4, up ¥9.8 per share YoY.

• Life Science segment delivered strong results, offsetting declines in Chemicals, Polymer Additives, and Semiconductor Materials.

• Overseas sales ratio reached 55.1%, reflecting continued global expansion.

• Comprehensive income surged 127.5% year-over-year to ¥20,378 million.

Financial highlights

• Ordinary profit for the first half was ¥19.9 billion, up 18.6% year-over-year.

• Gross profit improved to ¥56,292 million from ¥53,934 million YoY.

• Cash and deposits increased to ¥113.4 billion as of September 30, 2025.

• R&D costs for 1H were ¥8.9 billion, with a full-year forecast of ¥19.7 billion.

• Progress rate at end of H1: 44% for net sales, 46% for operating profit.

Outlook and guidance

• Full-year forecast reaffirmed: net sales ¥441 billion (+8.3%), operating profit ¥43 billion (+4.9%), profit attributable to owners ¥26.4 billion (+5.5%), and net profit per share ¥263.0.

• Annual dividend forecast is ¥104 per share, up from ¥100 in the previous year.

• Market uncertainty expected to persist due to trade, geopolitical, and financial risks.

• Life Science segment growth trend expected to continue; broad-based sales and profit increases forecasted except for semiconductors.